Cargando…

Conazoles

This review provides a historical overview of the analog based drug discovery of miconazole and its congeners, and is focused on marketed azole antifungals bearing the generic suffix “conazole”. The antifungal activity of miconazole, one of the first broad-spectrum antimycotic agents has been mainly...

Descripción completa

Detalles Bibliográficos
Autores principales: Heeres, Jan, Meerpoel, Lieven, Lewi, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6264770/
https://www.ncbi.nlm.nih.gov/pubmed/20657432
http://dx.doi.org/10.3390/molecules15064129
_version_ 1783375563671470080
author Heeres, Jan
Meerpoel, Lieven
Lewi, Paul
author_facet Heeres, Jan
Meerpoel, Lieven
Lewi, Paul
author_sort Heeres, Jan
collection PubMed
description This review provides a historical overview of the analog based drug discovery of miconazole and its congeners, and is focused on marketed azole antifungals bearing the generic suffix “conazole”. The antifungal activity of miconazole, one of the first broad-spectrum antimycotic agents has been mainly restricted to topical applications. The attractive in vitro antifungal spectrum was a starting point to design more potent and especially orally active antifungal agents such as ketoconazole, itraconazole, posaconazole, fluconazole and voriconazole. The chemistry, in vitro and in vivo antifungal activity, pharmacology, and clinical applications of these marketed conazoles has been described.
format Online
Article
Text
id pubmed-6264770
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-62647702018-12-04 Conazoles Heeres, Jan Meerpoel, Lieven Lewi, Paul Molecules Review This review provides a historical overview of the analog based drug discovery of miconazole and its congeners, and is focused on marketed azole antifungals bearing the generic suffix “conazole”. The antifungal activity of miconazole, one of the first broad-spectrum antimycotic agents has been mainly restricted to topical applications. The attractive in vitro antifungal spectrum was a starting point to design more potent and especially orally active antifungal agents such as ketoconazole, itraconazole, posaconazole, fluconazole and voriconazole. The chemistry, in vitro and in vivo antifungal activity, pharmacology, and clinical applications of these marketed conazoles has been described. MDPI 2010-06-09 /pmc/articles/PMC6264770/ /pubmed/20657432 http://dx.doi.org/10.3390/molecules15064129 Text en © 2010 by the authors; licensee MDPI, Basel, Switzerland. This article is an Open Access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Heeres, Jan
Meerpoel, Lieven
Lewi, Paul
Conazoles
title Conazoles
title_full Conazoles
title_fullStr Conazoles
title_full_unstemmed Conazoles
title_short Conazoles
title_sort conazoles
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6264770/
https://www.ncbi.nlm.nih.gov/pubmed/20657432
http://dx.doi.org/10.3390/molecules15064129
work_keys_str_mv AT heeresjan conazoles
AT meerpoellieven conazoles
AT lewipaul conazoles